Shinichiro Nishimura

This inventor holds 19 USPTO granted patents and 5 EPO patents, primarily in Glycoprotein Analysis. Top assignees: Sumitomo Bakelite Company Limited, Hokkaido University, Hitachi-High-Technologies Corporation. Active years: 1989-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shinichiro Nishimura. Retrieved from https://idiyas.com/inventor/shinichiro-nishimura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 21.1

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 55(Granted Patents)

Location History:

Sapporo, JP (1989 - 2017)
Hokkaido, JP (2011 - 2019)

Company Filing History:

7 out of 615

Sumitomo Bakelite Company Limited

Hitachi-High-Technologies Corporation

patents

4. 2 out of 2

Medicinal Chemistry Pharmaceuticals Co., Ltd.

patents

5. 2 out of 1,001

Shionogi Company Limited

patents

6. 1 out of 13

Carna Biosciences, Inc.

Murata Kikai Kabushiki Kaisha

where one patent can have more than one assignee

Years Active: 1989-2019

Loading Chart...

Areas of Expertise:

MUC4 Antibody

Sugar Chain Purification

Oligosaccharide Synthesizer

Polymer Particle

Glycoprotein Synthesis

Saccharide Composition

Azasugar Derivative

Galactosylceramide Analogs

Capture Agent

Sugar Chain-Trapping Molecule

External Skin Preparations

Slow-Releasing Preparation

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10272153 - Antibody to mucin 4 (MUC4) glycopeptide and uses thereof (2019-04-30),

2. 10239950 - Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof (2019-03-26),

3. 9714328 - Sugar chain-capturing substance and use thereof (2017-07-25),

4. 9683006 - Method of purifying/concentrating sugar chains with a sugar chain-trapping molecule and method of analyzing sugar chain structure (2017-06-20),

5. 9340651 - Sugar chain-capturing substance and use thereof (2016-05-17),

6. 9139607 - Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure (2015-09-22),

7. 8877454 - Apparatus for auto-pretreating sugar chain (2014-11-04),

8. 8232079 - Oligosaccharide synthesizer (2012-07-31),

9. 7985874 - Polymer particle (2011-07-26),

10. 7964687 - Oxylamino group-containing compound and polymer (2011-06-21),

11. 7964410 - Method for preparing analysis sample, analysis sample and sugar chain capture agent (2011-06-21),

12. 7883873 - Saccharide composition synthesizer (2011-02-08),

13. 7598372 - Synthesis of core sugar chain structure of asparagine-linked glycoprotein (2009-10-06),

14. 7556962 - Saccharide composition purification instrument (2009-07-07),

15. 7223779 - Azasugar derivative and drug containing the same as the active ingredient (2007-05-29),

Title: Innovations of Shinichiro Nishimura: Pioneering Antibody Development in Cancer Treatment

Introduction

Shinichiro Nishimura, based in Sapporo, Japan, is a distinguished inventor with a significant contribution to the field of cancer research through his innovative antibody inventions. With a total of 19 patents to his name, Nishimura has been at the forefront of developing methods that enhance cancer diagnosis and treatment.

Latest Patents

Among his notable advancements are two key patents focusing on antibodies: the first patent details an antibody that targets the MUC4 glycopeptide, which is preferentially expressed in cancer cells. This invention also describes a glycopeptide suitable for the production of this antibody, alongside methods for diagnosing, preventing, and treating cancer, particularly malignant tumors.

The second patent pertains to an anti-MUC1 antibody, characterized by its specificity for MUC1, which also shows high levels in cancer cells. This invention provides methods for the antibody’s production and application for cancer diagnosis and treatment, including a pharmacological composition featuring the monoclonal antibody as an active ingredient.

Career Highlights

Nishimura's professional journey includes influential roles at renowned institutions, such as Sumitomo Bakelite Company Limited and Hokkaido University. His work demonstrates a deep commitment to advancing medical science, notably in the development of innovative cancer therapies.

Collaborations

Throughout his career, Nishimura has collaborated with prominent colleagues, including Hiroaki Nakagawa and Hideyuki Shimaoka. These partnerships have enhanced his research efforts and have led to the successful realization of complex antibody innovations.

Conclusion

Shinichiro Nishimura stands out as a key innovator in the field of biotechnology, with his patents reflecting significant contributions to cancer treatment. His ongoing work promises to lead to further advancements in understanding and combating this challenging disease, showcasing the impact of innovative research on health care solutions.

Profile summary based on public USPTO records.